Eisai Clinical Trials

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

E7080-G000-205 Ph2

Study Overview

E7080
lenvatinib
NCT01136733, EU CTR 2010-019484-10
Mar 2012 - Jun 2014
Metastatic Renal Cell Carcinoma
Progression-free survival (PFS)

  • Males and females (age 18 years and over)

  • Completed

  • Phase 2

  • Czech Republic, Poland, Spain, United Kingdom, United States See more

Results

CSR Synopsis

Download PDF

Lay Summary

Download PDF
Publication reference citation

Motzer R et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial [plus supplementary appendix]. Lancet Oncology. 2015;16(15):1473-1482. DOI: 10.1016/S1470-2045(15)00290-9

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

CSDR Sharing is available for this study.

CSDR Availability
Clinical Trial Data

Redacted documents may be available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR